Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06941870 · ClinicalTrials.gov registry record · Phase 4
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
A Phase 4 study of Factor VIII Deficiency, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
- 13
- Study locations
NCT06941870: Recruiting Phase 4 study of Factor VIII Deficiency, sponsored by Sanofi.
NCT06941870 is a Phase 4 study of Factor VIII Deficiency that is actively recruiting participants, run by Sanofi. The registered enrollment target is 35 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). The trial reports 13 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06941870, a Phase 4 study of Factor VIII Deficiency, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
- 13
- Study locations
Study Summary
The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A. The study duration for each participant is approximately 12 months.
Primary Outcome
HEAD-US scoring system is a simplified ultrasound scanning procedure to image the elbow, knee, and ankle (index joints) and a scoring system based on an additive scale to define the joint status from disease activity and disease damage parameters to evaluate disease progression and monitor the results of treatment.
Conditions Studied
Interventions
- DRUG Efanesoctocog alfa
Study Locations (13)
Other
- Investigational Site Number : 3920002 - Hiroshima
- Investigational Site Number : 3920001 - Saitama
- Investigational Site Number : 3920004 - Tokyo
- Investigational Site Number : 1580003 - Kaohsiung City
- Investigational Site Number : 1580001 - Taichung
- Investigational Site Number : 1580002 - Taipei
Ontario
- Investigational Site Number : 1240003 - Hamilton
- Investigational Site Number : 1240004 - Hamilton
California
- Orthopedic Institute for Children- Site Number : 8400009 - Los Angeles
Indiana
- Innovative Hematology, Inc.- Site Number : 8400006 - Indianapolis
Iowa
- University of Iowa- Site Number : 8400004 - Iowa City
Ohio
- Ohio State University Hospital East- Site Number : 8400001 - Columbus
Kanagawa
- Investigational Site Number : 3920003 - Kawasaki
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-09-23 |
| Est. Completion | 2027-10-25 |
| Phase | Phase 4 |
What NCT06941870 shows while recruiting
NCT06941870 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Factor VIII Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Efanesoctocog alfa is the first listed.
NCT06941870 lists 13 locations in 7 states (Other, Ontario, California).
Frequently Asked Questions
What is clinical trial NCT06941870 about?
NCT06941870 is a clinical study titled "Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy". The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A. The study duration for each participant is approximat...
What is the current status of trial NCT06941870?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2025-09-23. Estimated completion is 2027-10-25.
What conditions does trial NCT06941870 study?
This clinical trial studies the following conditions: Factor VIII Deficiency.
What interventions are being tested in trial NCT06941870?
The interventions under investigation include: Efanesoctocog alfa (DRUG).
Who is sponsoring clinical trial NCT06941870?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06941870 being conducted?
This trial has 13 study locations across California, Indiana, Iowa, Ohio, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06941870's enrollment target sits among peer trials
35 1506th of 2000 higher than 482 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI